Hyderabad: Hyderabad occupies a key position in the Indian pharmaceutical sector, with the city contributing 30 percent of bulk medicine in the country. It also produces 30 percent of vaccines manufactured in the country. The next Hyderabad Pharma City will boost growth in the years to come.
KT Rama Rao, Minister of Industries, Telangana Government, at the inauguration of the fifth edition of the major pharmaceutical exhibition “Iphex 2017” in Hyderabad, said: “Of the proposed pharmaceutical group of 14,000 acres, about 8,000 Acres will be developed as part of Phase I. Focus will be on manufacturing, pharmaceutical research and development, testing facilities, centers of excellence, and the skills development center. “
Work on the environmental authorization will be completed in the coming months. The allocation of land to businesses will soon begin, he said.
The pharmaceutical cluster will become a base for bulk pharmaceutical and bulk formulations and will provide an optimal infrastructure for the industry, which includes zero liquid discharge, a common effluent treatment plant, uninterrupted water and a power supply, An area dedicated to social infrastructure, a first of its kind The regulatory enclave and the ecosystem respectful of the environment. Another important feature will be that the cluster itself will provide environmental permits to businesses.
Indian pharmaceutical products
The Indian pharmaceutical sector is the third largest in terms of volume and 13th in value terms. There are 3,000 pharmaceutical companies in India that operate about 10,500 manufacturing units. Nearly 20% of global generic exports come from India. The industry has a healthy growth rate of 11.4 percent year-on-year. Outside the United States, India has most plants approved by the US Food and Drug Administration (USFDA). Globally, affordable health care is a priority for governments and India has helped provide low-cost quality drugs.
Projections indicate that the Indian pharmaceutical sector will remain third in terms of overall growth and sixth in size by 2020. With the highly regulated markets of the world, the United States and Europe Harmonize and standardize their regulations, countries such as India will benefit while companies operating in the country are already compliant with USFDA, the European Medicines Agency, Good Manufacturing Practices (GMPC) and standards Of the World Health Organization (WHO).
Click here for Latest Telangana News
Regarding the participation of regulators and buyers at Iphex 2017 (held 27-29 April), KTR stated that active discussions with foreign regulators will help Indian companies better understand their regulations and contribute to further improvements conformity.